Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Zhejiang Heze Pharmaceutical Technology

Request full access

Pharmaceutical R&D, clinical trials, and MAH services.

ChinaFounded 2006Biotech & Life Sciences

About Zhejiang Heze Pharmaceutical Technology

Zhejiang Heze Pharmaceutical Technology Co., Ltd. is a service-oriented platform company centered on drug research and development, also engaging in drug marketing authorization holder (MAH) certification and transfer. Established on October 27, 2006, by Ni Sheng, the company is headquartered in Hangzhou, China. Ni Sheng, who holds a bachelor's degree in pharmacy, served as a technician and project leader at the Zhejiang Provincial Institute of Traditional Chinese Medicine from 1994 to 2003 before starting his entrepreneurial journey. The company's business model is driven by both R&D services and industrial operations, offering a comprehensive suite of services that includes pharmaceutical research, clinical trials, and registration and declaration. It operates as a Contract Research Organization (CRO) and was a pioneer in implementing China's MAH system, which allows research institutions to hold drug marketing licenses. Heze Pharmaceutical obtained the first Drug Manufacturing License for a pharmaceutical R&D institution in China, enabling it to provide integrated R&D services and solutions for global MAH clients. Heze Pharmaceutical's services cover the entire pharmaceutical industry chain. Core services include generic drug development, consistency evaluation of generic drugs, innovative drug development, and clinical trial services. The firm has established various technology platforms for small molecule drugs, peptide drugs, and different drug delivery systems like oral, injection, and topical applications. It also provides Contract Development and Manufacturing Organization (CDMO) services and third-party testing for aspects like genotoxic impurities and elemental impurities. With experience in over 1,000 projects, its therapeutic areas include liver disease, gynecology, diabetes, and oncology. The company has developed a portfolio of its own products, including both innovative and generic drugs. Through its subsidiaries, such as Kunyuan Pharmaceutical and Yiyuan Pharmaceutical, it handles MAH conversion, clinical research, and other specialized services.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
15
Open positions
5
Dealroom signal
24.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Drug Development, Chronic Disease, Biotech and Pharma
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Feb 2026 $0 — Taizhou Capital Group ↗
EARLY VC✓Equity / VC Sep 2023 $28M $110M CITIC Capital · JIC Investment · Fu Zhe Capital · Zhengzhou High-tech Fund ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Zhejiang Heze Pharmaceutical Technology website traffic

Latest recorded traffic for Zhejiang Heze Pharmaceutical Technology is 120 monthly website visits, down 33.3% over the last three months. Zhejiang Heze Pharmaceutical Technology's team grew 0% over the past year.

Latest monthly visits120 3-month web change-33.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Zhejiang Heze Pharmaceutical Technology in its local ecosystem

Live from Dealroom

The Zhejiang Heze Pharmaceutical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • CITIC Capital
  • JIC Investment
  • Fu Zhe Capital
  • Zhengzhou High-tech Fund

Other known investors1 additional known investor

  • Taizhou Capital Group
Employees 15 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Zhejiang Heze Pharmaceutical Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Zhejiang Heze Pharmaceutical Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.